The rate of relapses in children with pediatric-onset multiple sclerosis (POMS) tends to increase around the time that menstruation begins, a new study reports. The findings suggest hormonal changes at the onset of puberty may trigger higher disease activity. The use of oral and infusion disease-modifying therapies (DMT)…

A higher intake of whole grain food is significantly associated with a lower likelihood of developing pediatric-onset multiple sclerosis (MS), according to a study led by researchers in Canada. Conversely, an overall more pro-inflammatory diet — one containing higher amounts of fats and proteins — was linked to increased…

High-efficacy therapies given early can significantly reduce the risk of disability worsening in children and adolescents with multiple sclerosis (MS), particularly when treatment is started while patients have fairly minimal disability, according to a new study. While lower-efficacy therapies were also associated with a reduced risk of disability progression…

Use of high-efficacy therapies can lower the risk of disability progression in people with childhood-onset multiple sclerosis (MS), particularly if given in early disease stages when disabling symptoms are negligible. That’s according to data shared at the 9th joint meeting of the European Committee for Treatment and…

Ocrevus (ocrelizumab) is a safe and effective treatment for patients under 18 with highly active relapsing-remitting multiple sclerosis (RRMS), a small study from Turkey suggests. Over about 2.5 years of the treatment, these pediatric patients experienced no relapses or MRI activity, and their disability level also improved, indicating…

In this installment of our “Expert Voices” series, Multiple Sclerosis News Today asked Tanuja Chitnis, MD, to answer some of your questions about pediatric multiple sclerosis (MS). Chitnis is a board-certified neurologist specializing in multiple sclerosis-related neuroimmunological disorders. Chitnis’s interest in children with MS led her to create…

About CA$1.35 million ($1.07 million) has been invested in a project that seeks to understand the effects of multiple sclerosis (MS) on a group of people with pediatric-onset disease as they move into adulthood. The three-year investment was from Biogen Canada and Roche Canada — each providing about…

Children and young adults who spend more time outdoors in the sunshine are less likely to develop multiple sclerosis (MS), according to a new study, which suggests that sunshine might help to protect against the disease. “Advising regular time in the sun of at least 30 minutes daily especially…

People who develop multiple sclerosis (MS) in childhood have more difficulty recognizing words and faces than healthy individuals, a small study found. The volume of certain structures of the limbic system — a part of the brain involved in memory and emotion — is smaller in those with MS,…

Multiple sclerosis and its associated fatigue negatively affect school performance, mental health, and physical and social functioning in children and adolescents with the disease, according to a review study. Pediatric-onset multiple sclerosis (POMS) also was associated with negative effects on social functioning, mental health, and quality of life in…

A computer-based training program that exercises distinct components of attention and working memory can improve cognition in young people with pediatric-onset multiple sclerosis (POMS), a new study indicates. Findings also support a common pencil-and-paper measure of cognition, called the Symbol Digit Modalities Test (SDMT), in detecting clinically meaningful changes…

People who develop multiple sclerosis (MS) as children are more likely to attain lower education levels, earn less in the workplace, and be more reliant on disability benefits later in life, new research shows. These findings were published in JAMA Neurology, in the study, “Long-term Socioeconomic…

Editor’s note: The Multiple Sclerosis News Today news team is providing in-depth and unparalleled coverage of the virtual ACTRIMS Forum 2021, Feb. 25–27. Go here to see all the latest stories from the conference. Spending more time in the summer sun and living in generally sunnier places appears to provide protection against…

Despite having more severe first and second relapses, children with relapsing-remitting multiple sclerosis (RRMS) tend to recover better than adults with the disease, according to a study. Better recovery in children may be linked to the activation of genes that, in turn, impair the activation of immune cells driving…

A variant of the HLA-DRB1 gene — called HLA-DRB1*03 — appears to predispose people to developing multiple sclerosis (MS) in childhood, and to correlate with greater disease activity among those who do, a study in Greek patients suggests. The research also points to a protective role of one other variant of this…

A post in one of the MS social media groups I follow recently asked whether kids can have MS. The writer was worried about her 3-year-old. One commenter replied that her son was diagnosed when he was 9. But, she wrote, his symptoms actually began to appear when he…

FDA Will Review New Drug Application of Diroximel Fumarate for Relapsing Forms of MS The good news: Another disease-modifying therapy (DMT) has taken a step toward approval in the U.S. The discouraging news: It’s another DMT designed to treat relapsing forms of multiple sclerosis. More than a…

NICE Postpones Final Opinion on Adding Ocrevus to Public Health System for PPMS Patients in UK This last-minute reprieve from the agency that dictates which medications may be prescribed for patients of the U.K.’s National Health Service (NHS) is welcome news. Last summer, the National Institute for…

Children exposed to certain air pollutants in urban areas or some household chemicals are at higher risk of developing multiple sclerosis (MS) during childhood or adolescence, two new research studies suggest. The studies “Urban air quality and associations with pediatric multiple sclerosis” and…

Until about a week ago, no medication was approved in the U.S. to treat patients with pediatric-onset MS (POMS). Now there is one. The Food and Drug Administration (FDA) has given its OK to use Gilenya (fingolimod) to treat relapsing MS in children and adolescents starting at…

In a U.S. nationwide case study, a team of researchers found evidence for a potential link between viral infections during childhood, vitamin D deficiency, and the risk of developing multiple sclerosis (MS). The study, “Environmental risk factors associated with pediatric MS: The role of remote viral infections and vitamin D revisited,” was recently…

The immune system B-cells responsible for producing antibodies are different in those who develop multiple sclerosis (MS) as children, than in those who develop it as adults, a study shows. The research, “B-cell populations discriminate between pediatric- and adult-onset multiple sclerosis,” was published in the journal Neurology: Neuroimmunology & NeuroInflammation. Because only 3…